

1 **A Randomized, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of VIR-2482**
2 **in Healthy Adults for Prevention of Influenza A Illness (PENINSULA)**

3
4 Susanna K. Tan,¹ Deborah Cebrik,¹ David Plotnik,¹ Maria L. Agostini,¹ Keith Boundy,¹ Christy
5 M. Hebner,¹ Wendy W. Yeh,¹ Phillip S. Pang,¹ Jaynier Moya,² Charles Fogarty,³ Manuchehr
6 Darani,⁴ Frederick G. Hayden⁵

7
8 ¹Vir Biotechnology, Inc., San Francisco, California, USA; ²Pines Care Research Center, Inc.,
9 Pembroke Pines, Florida, USA; ³Spartanburg Medical Research, Spartanburg, South Carolina,
10 USA; ⁴Marvel Clinical Research, Long Beach, California, USA; ⁵University of Virginia School
11 of Medicine, Charlottesville, Virginia, USA

12
13 **Corresponding author:**

14 Susanna K. Tan

15 Vir Biotechnology, Inc.

16 1800 Owens St

17 San Francisco, CA 94158 USA

18 Telephone: (415) 906-4324

19 Email: stan@vir.bio

20

21 **Key points**

22 Prophylactic administration of 1200 mg of VIR-2482, an engineered human monoclonal
23 antibody targeting a highly conserved epitope on the stem region of influenza A hemagglutinin,
24 did not significantly reduce risk of influenza-like illness from influenza A virus in healthy adults.

25

26 **Abstract**

27 **Background:** Influenza A results in significant morbidity and mortality. VIR-2482, an
28 engineered human monoclonal antibody with extended half-life, targets a highly conserved
29 epitope on the stem region of influenza A hemagglutinin, and may protect against seasonal and
30 pandemic influenza.

31 **Methods:** This double-blind, randomized, placebo-controlled, phase 2 study examined the safety
32 and efficacy of VIR-2482 for seasonal influenza A illness prevention in unvaccinated healthy
33 adults. Participants (N = 2977) were randomized 1:1:1 to receive VIR-2482 450 mg, VIR-2482
34 1200 mg, or placebo via intramuscular (IM) injection. Primary and secondary efficacy endpoints
35 were the proportions of participants with reverse transcriptase-polymerase chain reaction (RT-
36 PCR)–confirmed influenza A infection and either protocol-defined influenza-like illness (ILI)
37 and Centers for Disease Control and Prevention (CDC)–defined ILI or World Health
38 Organization (WHO)–defined ILI, respectively.

39 **Results:** VIR-2482 450 mg and 1200 mg prophylaxis did not reduce the risk of protocol-defined
40 ILI with RT-PCR–confirmed influenza A versus placebo (relative risk reduction [RRR], 3.8%
41 [95% CI: -67.3, 44.6] and 15.9% [95% CI: -49.3, 52.3], respectively). At the 1200 mg dose, the
42 RRRs in influenza A illness were 57.2% [95% CI: -2.5, 82.2] using CDC-ILI and 44.1% [95%
43 CI: -50.5, 79.3] using WHO-ILI definitions, respectively. Serum VIR-2482 levels were similar
44 regardless of influenza status; variants with reduced VIR-2482 susceptibility were not detected.
45 Local injection-site reactions were mild and similar across groups.

46 **Conclusion:** VIR-2482 1200 mg IM was well tolerated but did not significantly prevent
47 protocol-defined ILI. Secondary endpoint analyses suggest this dose may have reduced influenza
48 A illness.

49 **Keywords:** Influenza A; monoclonal antibody; VIR-2482

50 **Trial registration:** ClinicalTrials.gov identifier, NCT05567783

51

52 **Introduction**

53 According to the World Health Organization (WHO) approximately 1 billion annual cases of
54 seasonal influenza occur globally. Of these, an estimated 3 to 5 million cases are severe, with up
55 to 650,000 deaths per year [1]. Influenza A and B are both responsible for seasonal epidemics,
56 but influenza A infections account for the majority of hospitalizations and are the only influenza
57 type to cause pandemics [2]. Some patient groups are at high risk of influenza-associated
58 hospitalizations and mortality, including the elderly, immunocompromised hosts, and those with
59 certain comorbidities [3-5].

60 Currently available seasonal influenza vaccines are influenza strain-specific,
61 incompletely protective due to strain mismatch, and often inadequately immunogenic, especially
62 in high-risk groups like the elderly and immunocompromised [6]. Specifically, vaccine
63 effectiveness against medically attended influenza illness ranged from 19% to 60% in the United
64 States between the 2009 to 2023 influenza seasons [7]. Therefore, we hypothesized that an
65 immunoprophylactic antibody with long half-life and activity against a broad range of influenza
66 A viruses could provide greater protection and obviate the need for updates to match the
67 prevalent circulating strains, especially in individuals at high-risk of complications. Additionally,
68 such a neutralizing antibody could facilitate a rapid response to an influenza A pandemic [8].

69 VIR-2482 is a neutralizing, engineered human immunoglobulin G (IgG) monoclonal
70 antibody (mAb) that targets a highly conserved epitope on the stem region of the influenza A
71 hemagglutinin (HA) protein [9, 10]. Epidemiologically, HA-stem binding antibodies have been
72 shown to correlate with protection from illness [11] and are the focus of ongoing efforts to create
73 universal influenza vaccines [8, 12].

74 VIR-2482 and its parent mAb bind to HAs representing all 18 influenza A subtypes and
75 neutralize a broad panel of H1N1 and H3N2 influenza viruses spanning >100 years of antigenic
76 evolution. Administration of VIR-2482 reduced morbidity and mortality from infection by
77 seasonal and zoonotic strains of influenza in mice, ferrets, and macaques [9, 13-15]. VIR-2482 is
78 engineered to include an Fc LS mutation (M428L/N434S) that extends the elimination half-life
79 ($T_{1/2}$) through increased FcRn-mediated antibody recirculation [9].

80 In a phase 1 study in healthy volunteers (ClinicalTrials.gov Identifier: NCT04033406),
81 VIR-2482 doses of 60 to 1800 mg via intramuscular (IM) injection showed favorable local and
82 systemic tolerability, with few injection-site reactions [10]. Median time to maximum plasma
83 concentration of VIR-2482 ranged from 7.0 to 12.5 days, and median plasma $T_{1/2}$ was 57.1 to
84 70.6 days across dosing cohorts, indicating the potential for administration once per influenza
85 season.

86 We undertook this proof-of-concept, phase 2 trial to evaluate the safety, tolerability, and
87 efficacy of VIR-2482 in preventing influenza A illness in healthy adults who had not received a
88 seasonal influenza vaccine. Since vaccination was prohibited, participants were required to be at
89 low risk of developing serious influenza-related complications.

90

91 **METHODS**

92 **Study Design**

93 This was a double-blind, randomized, placebo-controlled, dose-ranging study conducted at 53
94 centers in the United States during the 2022 to 2023 Northern Hemisphere influenza season. The
95 study was conducted in accordance with the principles of the Declaration of Helsinki and the

96 study protocol was approved by the relevant institutional ethics committees (authorizing body:
97 WCG Institutional Review Board). All participants provided written informed consent.

98

99 **Participants**

100 Males and nonpregnant/nonlactating females aged 18 to <65 years were eligible to participate if
101 they were in good health as determined from medical history. Key inclusion criteria included
102 body mass index (BMI) 18.0 to 35.0 kg/m² and no clinically significant findings from physical
103 examination, 12-lead electrocardiogram, and laboratory values. Participants were excluded if
104 they had prior or planned receipt of any influenza vaccine for the upcoming season, history or
105 clinical evidence of conditions considered high risk for developing influenza-related
106 complications, or confirmed influenza infection within 3 months of randomization (see
107 Supplementary Methods).

108

109 **Antibody Administration and Safety Monitoring**

110 VIR-2482 or saline placebo was administered as 2 separate 4-mL IM injections. Participants
111 were randomized 1:1:1 to VIR-2482 450 mg (1 dose of VIR-2482 and 1 dose of placebo), VIR-
112 2482 1200 mg (2 doses of VIR-2482) or placebo (2 doses of placebo) on Day 1. These doses
113 were selected based on the acceptable safety and tolerability of VIR-2482 doses in the phase 1
114 study and target serum concentrations estimated from in vitro neutralization data [10]. VIR-2482
115 was administered as a 150-mg/mL solution. The preferred injection site was the thigh, with the
116 buttock as an alternative.

117 Participants remained at the clinical study site for ≥ 2 hours postdose to assess safety,
118 including solicited local tolerability at the injection sites performed at 1-hour postdose.
119 Following discharge, participants completed an electronic diary card from Days 1 to 7 to record
120 injection site and systemic reactions and body temperature. Follow-up visits were conducted at 1,
121 4, and 12 weeks postdosing and at the end of the influenza season (EOIS).

122 Adverse events (AEs) were recorded through the end of the study, with severity assessed
123 according to the Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled
124 in Preventative Vaccine Clinical Trials [16]. Immunogenicity of VIR-2482 was evaluated
125 according to incidence and titers of antidrug antibodies (ADAs) using validated methods [10].

126

127 **Illness Surveillance**

128 Participants completed an electronic diary for influenza-like illness (ILI) symptoms twice per
129 week from Day 1 through EOIS (April 16, 2023). Signs and symptoms included sore throat,
130 cough, sputum production, wheezing, difficulty breathing, temperature $>37.8^{\circ}\text{C}$, chills,
131 weakness, or myalgia. Participants experiencing any ILI symptoms were requested to visit the
132 study center within 3 days of symptom onset for nasopharyngeal swab (NPS) collection.
133 Influenza A was confirmed by reverse transcriptase-polymerase chain reaction (RT-PCR) using a
134 sponsor-provided point-of-care device (Xpert-Xpress CoV-2/RSV/Flu plus; Cepheid; Sunnyvale,
135 CA) or a central virology laboratory assay (Respiratory Panel 1; Seegene; Seoul, South Korea)
136 performed at DDL Diagnostic Laboratories (Rijswijk, Netherlands). Participants with ILI were
137 managed according to local standard of care, and symptoms were followed-up daily via
138 telephone through Day 10 following initial presentation. Symptom severity of ILI was

139 documented using the Influenza Intensity and Impact Questionnaire Flu-iiQ™ [17] administered
140 from Day 1 of symptom onset through Day 10.

141

142 **Pharmacokinetics**

143 Serum samples for pharmacokinetics (PK) and immunogenicity analyses were collected predose
144 and at the follow-up visits. NPS for PK analysis [10] were collected from all participants at the
145 EOIS visit and at Weeks 1, 4, and 12 from a subset of participants in an optional PK substudy. In
146 participants with ILI, additional samples for PK, ADA, and virologic analyses were collected at
147 the ILI confirmation clinic visit.

148

149 **Outcomes**

150 The primary efficacy endpoint was the proportion of participants with RT-PCR positivity for
151 influenza A and protocol-defined ILI. The protocol definition required ≥ 1 respiratory symptom
152 (sore throat, cough, sputum production, wheezing, or difficulty breathing) and ≥ 1 systemic sign
153 or symptom (temperature $>37.8^{\circ}\text{C}$, chills, weakness, or myalgia). Prespecified secondary
154 efficacy endpoints were the proportions of participants with RT-PCR–confirmed influenza A and
155 ILI as defined by the Centers for Disease Control and Prevention (CDC; temperature $>37.8^{\circ}\text{C}$
156 with sore throat or cough and RT-PCR confirmation) and WHO (temperature $>38^{\circ}\text{C}$ with cough
157 and RT-PCR confirmation).

158 Exploratory endpoints included the severity and duration, as the time of onset of first
159 symptom through when all respiratory symptoms were resolved for ≥ 24 hours, of participant-
160 reported ILI signs and symptoms with the Flu-iiQ™ instrument [17]. Virologic analyses on NPS

161 samples determined the proportion of participants with RT-PCR–confirmed influenza A by virus
162 subtype and assessed emergence of virus variants with reduced susceptibility to VIR-2482. Next-
163 generation sequencing of the influenza A HA gene was performed at DDL Diagnostic
164 Laboratories (Rijswijk, Netherlands). Virus successfully cultured in MDCK cells was assessed
165 for reduced susceptibility using an in vitro neutralization assay at Viroclinics Biosciences
166 (Rotterdam, Netherlands) [18]. Sequence and phenotypic results were compared with respective
167 subtype vaccine reference strains (H1N1: A/Victoria/2750/2019; H3N2: A/Darwin/9/2021 and
168 A/Darwin/6/2021, respectively).

169

170 **Statistical Analysis**

171 A sample size of approximately 3000 participants was needed to provide approximately 80%
172 power to detect VIR-2482 efficacy (a true relative risk reduction [RRR] of 70%) of 1 VIR-2482
173 dose level compared with placebo, assuming an attack rate of $\geq 2.25\%$ in the placebo group [19,
174 20]. Efficacy and safety were analyzed in all randomized participants receiving any amount of
175 study drug or placebo. Efficacy was assessed based on the study intervention to which
176 participants were randomly assigned, and safety was assessed based on the intervention received.
177 Details on primary and secondary estimands and statistical analyses are provided in the
178 Supplementary Methods.

179 A modified Poisson regression with robust variance was used as the efficacy analysis
180 model to estimate the relative risk of the incidence of protocol-/CDC-/WHO-defined ILI with
181 RT-PCR–confirmed influenza A in each VIR-2482 group compared with the placebo group, with
182 treatment group as the only factor in each model. A hierarchical fixed sequence testing procedure

183 was used to control the overall type I error as outlined in the Supplementary Methods. Formal
184 comparisons precluded by the hierarchical testing strategy were considered descriptive.

185

186 **Results**

187 *Participants and Disposition*

188 Between October 13, 2022, and January 6, 2023, participants (N = 2977) were randomized, and
189 2956 (99.3%) received study intervention (**Figure 1**). Across treatment groups, mean age was
190 39.5 years and 54% were female (**Table 1**). Study drug or placebo was administered in the thigh
191 in approximately 78% of participants. Through the end of study, discontinuation rates were <5%
192 and comparable across treatment groups.

193

194 *Efficacy Outcomes*

195 The primary endpoint of protocol-defined ILI with RT-PCR confirmed influenza A was observed
196 in similar numbers of participants across groups (**Table 2**). A nonsignificant RRR of 15.9%
197 (95% CI: -49.3, 52.6) comparing VIR-2482 1200 mg versus placebo was observed. Predefined
198 subgroup analyses between these 2 groups showed RRRs consistent with that of the overall
199 population (**Supplementary Figure 1**). In the VIR-2482 1200 mg group, RRRs versus placebo
200 for CDC- and WHO-defined ILI with RT-PCR–confirmed influenza A were 57.2% (95% CI: -
201 2.5, 82.2) and 44.1% (95% CI: -50.5, 79.3), respectively (**Table 2**).

202 To investigate the impact of pre-existing infections or infections that may have been
203 acquired prior to VIR-2482 achieving adequate tissue distribution, we conducted posthoc

204 analyses excluding 10 cases of protocol-defined ILI, 5 cases of CDC-defined ILI, and 4 cases of
205 WHO-defined ILI that occurred within 7 days following study drug administration. Numerically
206 higher RRRs of ILI were observed in the VIR-2482 1200 mg group (protocol-defined: 34.0%
207 [95% CI: -25.7, 65.3]; CDC-defined: 64.9% [95% CI: 3.9, 87.2]; WHO-defined: 42.9% [95% CI:
208 -69.7, 80.8]; **Supplementary Table 1**).

209 Most participants with protocol-defined ILI reported moderate to severe symptoms.
210 Symptom severity of ILI measured by FluiiQ™ was similar across groups (**Supplemental Table**
211 **2**). Participants who received VIR-2482 1200 mg had a numerically shorter time to resolution of
212 protocol-defined ILI than participants who received placebo (median: 85.8 h [interquartile range
213 (IQR): 57.7-137.2] vs 111.9 h [IQR: 72.1-130.4]). No influenza-related hospitalizations or deaths
214 were reported.

215

216 *Safety*

217 Treatment-emergent AEs (TEAEs) were reported in 62% to 65% of participants across study
218 groups (**Table 3**). The most frequently reported TEAEs (>5% of participants in any group) were
219 upper respiratory tract infection, COVID-19, oropharyngeal pain, cough, viral infection, and
220 myalgia. Treatment-related TEAEs were reported in $\leq 2\%$ of participants and were similarly
221 distributed across groups. Serious TEAEs were uncommon ($\leq 1\%$ across groups), and none were
222 considered related to study treatment. Five deaths occurred during the study, and none were
223 considered related to treatment.

224 Incidences of solicited injection-site reactions at 1-hour postdose were <10% in all 3
225 groups (**Supplementary Table 3**). Grade 1 (mild) injection-site pain was the most common self-

226 reported injection-site reaction (placebo, 5.6%; VIR-2482 450 mg, 6.1%; VIR-2482 1200 mg,
227 8.4%) during the on-site assessment. Mild injection-site pain was also the most common
228 injection-site reaction reported on the electronic diary card during Days 1 to 7 (placebo, 22.6%;
229 VIR-2482 450 mg, 24.5%; VIR-2482 1200 mg, 23.9%; **Supplementary Table 4**). The most
230 common participant-reported systemic reactions included mild myalgia (12.3%-14.9%), mild
231 headache (12.5%-14.0%), and mild malaise (9.8%-10.3%; **Supplementary Table 5**). No
232 treatment-emergent anaphylaxis events were reported. Incidences of treatment-emergent clinical
233 laboratory and vital signs abnormalities were similar across groups.

234

235 *Virologic Analyses*

236 Among participants with protocol-defined ILI with RT-PCR–confirmed influenza A, H3 subtype
237 virus was detected in 56% to 72% and H1 subtype in 16% to 36% of illnesses across study
238 groups; 8% to 19.1% of illnesses had an unknown influenza A subtype (**Supplementary Table**
239 **6**).

240 Sequence and phenotypic data availability are described in **Supplementary Table 7**.
241 Influenza A virus isolates, including the small number where a VIR-2482 epitope amino acid
242 substitution was detected by sequence analysis, retained susceptibility to VIR-2482 with fold
243 changes in half maximal effective concentration (EC₅₀) ranging from 0.23 to 2.55 compared with
244 the respective subtype vaccine reference strain in vitro.

245

246 *Pharmacokinetics*

247 Following VIR-2482 1200 mg, median serum T_{\max} was 6.95 days, geometric mean serum C_{\max}
248 was 111 $\mu\text{g/mL}$ ($\text{CV}\% = 52.1\%$), and geometric mean serum concentration at EOIS was 18.5
249 $\mu\text{g/mL}$ ($\text{CV}\% = 98.8$). Median $T_{1/2}$ was 54.7 to 55.4 days across VIR-2482 doses. Compared
250 with gluteal administration, thigh injection resulted in 79.9% higher C_{\max} and 43.8% higher area
251 under the curve (AUC) for the 450 mg dose and 97.5% higher C_{\max} and 55.6% higher AUC for
252 the 1200 mg dose (**Supplementary Table 8**).

253 Serum and NPS concentration-time data through 180 days postdose are displayed in
254 **Figure 2** and NPS:serum ratios are displayed in **Supplemental Figure S2**. The NPS
255 concentrations of VIR-2482 averaged 2.1% to 7.8% of within-subject serum concentrations
256 across doses and time points. VIR-2482 recipients who experienced breakthrough influenza A
257 illness had serum levels that were comparable to those who did not (**Supplemental Table 9**).

258

259 *Immunogenicity*

260 The incidence of ADA was 5.4% (53/980) in the 450 mg group and 5.1% (51/992) in the 1200
261 mg group. A >4-fold increase in ADA titer relative to baseline was observed in 1 participant
262 receiving VIR-2482 1200 mg, while the titer of all other pre-existing ADAs was unaffected by
263 treatment. Further, ADAs were not correlated with AEs, injection-site reactions, or aberrant PK
264 in any participant (data not shown).

265

266 **Discussion**

267 Neutralizing mAbs have demonstrated the ability to prevent symptomatic respiratory diseases,
268 such as COVID-19 in adults [21] and respiratory syncytial virus (RSV) in infants [22]. Broadly

269 neutralizing HA-stem binding antibodies are recognized as potential pandemic influenza
270 countermeasures [13, 23], and studies of such antibodies have shown therapeutic efficacy in
271 experimentally induced human influenza infections [24, 25] but have demonstrated inconsistent
272 efficacy in treating uncomplicated seasonal influenza [26-28]. The current trial found that
273 prophylactic IM VIR-2482 administration was generally well tolerated, but did not significantly
274 protect against protocol-defined ILI with RT-PCR–confirmed influenza A compared with
275 placebo. Several explanations could account for the lack of significant clinical efficacy observed
276 in this study.

277 Two potential contributory factors were the early onset of influenza activity in the 2022
278 to 2023 influenza season [29] that coincided with study enrollment and dosing and the known lag
279 between maximal serum and tissue concentrations following IM dosing. When RT-PCR–
280 confirmed illnesses that occurred <7 days after dosing were excluded, posthoc analyses showed
281 greater reductions in ILI in VIR-2482 1200 mg recipients, including 65% RRR of the CDC-
282 defined ILI cases in the 1200 mg group compared with placebo. These results suggest that early
283 ILIs could have been due to either incubating infections prior to VIR-2482 dosing or infections
284 acquired during the window prior to adequate tissue distribution. In addition, we noted that
285 participants who received VIR-2482 1200 mg had a numerically shorter time to resolution of
286 protocol-defined ILI than participants who received placebo, suggesting clinical activity at this
287 dose.

288 The apparent dose-response observed in those who received VIR-2482 1200 mg versus
289 450 mg suggests the possibility that the onset and durability of protection was potentially limited
290 by the drug levels achieved in relevant tissue compartments. The VIR-2482 1200 mg dose
291 selection was based on modelling using in vitro EC₉₀ data that estimated it would provide

292 antiviral activity for >8 months [10]. Additional PK-pharmacodynamics analyses are needed to
293 better understand the tissue distribution of VIR-2482 and the optimal drug levels needed in the
294 respiratory tract.

295 The serum and nasopharyngeal exposures of VIR-2482 observed in this study were
296 comparable to those reported in the phase 1 study of healthy volunteers [10]. Also, the overall
297 incidence of ADAs was low and not correlated with reduced serum concentrations or incidence
298 of infections. Consequently, dosing errors, manufacturing concerns, or aberrant PK are unlikely
299 explanations for trial failure. Viral resistance was also unlikely to explain the lack of efficacy,
300 since viruses cultured from participants with influenza A infections retained susceptibility to
301 VIR-2482 compared with respective subtype reference viruses in vitro.

302 One hypothesis that may account for these results is that the antiviral activities of HA-
303 stem antibodies observed in vitro or in in vivo animal models do not translate into clinically
304 meaningful benefit when administered to unvaccinated healthy adults for prophylaxis of
305 symptomatic infection. The HA-stem antibodies that block fusion of the endocytosed virion
306 within cells may not be as effective at preventing symptomatic infection compared with the
307 head-binding HA antibodies typically induced by seasonal vaccines that block receptor binding.

308 An additional hypothesis is that VIR-2482 has clinically meaningful activity, but the
309 selected endpoints, dose, study population, or timing did not enable a positive trial result.
310 Unvaccinated healthy adults were selected as the trial population in this study to better
311 understand the tolerability profile and clinical activity of VIR-2482 without prior vaccination.
312 The prespecified CDC-defined secondary endpoint, which requires a temperature >37.8°C,
313 demonstrated numerically a 57.2% RRR in symptomatic RT-PCR–confirmed infection in VIR-
314 2482 1200 mg recipients versus the 15.9% RRR observed for the primary endpoint. This raises

315 the possibility that VIR-2482 could be more effective in preventing severe or systemic influenza
316 illness in a more vulnerable patient population than unvaccinated healthy adults. Indeed, this
317 concept has been demonstrated with mAbs targeting RSV in infants, where the primary endpoint
318 is not mild symptomatic illness, but medically attended lower respiratory tract infection [22].
319 COVID-19 vaccines and mAbs have also demonstrated effectiveness against severe disease but
320 are less effective in protecting against mild illness [30-32].

321 In conclusion, although VIR-2482 was well tolerated, it did not significantly prevent
322 influenza A illness in healthy unimmunized adults at IM doses up to 1200 mg. There remains a
323 clinical need for long-duration prophylactic interventions that provide protection against the
324 morbidity and mortality of influenza in individuals at high-risk of complications. The findings
325 from this trial provide valuable insights to support the future development of broad spectrum
326 mAbs for the prevention of influenza illness.

327

328 **Funding**

329 This work was supported by Vir Biotechnology, Inc. and with federal funds from the Department
330 of Health and Human Services (HHS); Administration for Strategic Preparedness and Response
331 (ASPR); and Biomedical Advanced Research and Development Authority (BARDA) under
332 contract number 75A50122C00081. The findings and conclusions herein are those of the authors
333 and do not necessarily represent the views of the HHS or its components.

334

335 **Acknowledgements**

336 The authors thank all study participants, investigators, site personnel, and operational staff. The
337 authors also thank Jeanne McKeon, PhD, of Lumanity Scientific Inc., for medical writing and
338 editorial support, which was funded by Vir Biotechnology, Inc.

339

340 **Author Contributions**

341 Susanna K. Tan, Deborah Cebrik, David Plotnik, Maria L. Agostini, Keith Boundy, Christy M.
342 Hebner, Wendy W. Yeh, Philip S. Pang, and Frederick G. Hayden conceptualized and designed
343 the study. Jaynier Moya, Charles Fogarty, and Manuchehr Darani acquired and analyzed data.
344 Deborah Cebrik conducted the statistical analyses. All authors interpreted data, drafted the
345 manuscript, and critically reviewed and revised the manuscript for important intellectual content.
346 All authors had full access to all the data in the study, take responsibility for the accuracy of the
347 analysis, and had authority over manuscript preparation and the decision to submit the
348 manuscript for publication.

349

350 **Conflict of Interest Disclosures**

351 Susanna K. Tan, Deborah Cebrik, David Plotnik, Maria L. Agostini, Keith Boundy, Wendy W.
352 Yeh, and Philip S. Pang are employees of Vir Biotechnology, Inc and report stock ownership in
353 Vir Biotechnology, Inc. Christy M. Hebner is a former employee and shareholder of Vir
354 Biotechnology, Inc. and is a coauthor on select Vir Biotechnology, Inc. patents. Jaynier Moya
355 and Manuchehr Darani have nothing to disclose. Charles Fogarty reports receiving grant support
356 from Vir Biotechnology, Inc. for conduct of the clinical trial. Frederick G. Hayden has served as
357 a nonpaid consultant to Vir Biotechnology, Inc. and other companies involved in developing

358 influenza therapeutics or vaccines, including Appili, Arcturus, Gilead, GSK, Janssen/JNJ,
359 MedImmune, Medivector/Fujifilm, Merck, Ridgeback, Roche/Genentech, and Visterra. Cidara,
360 Enanta, Shionogi, and Versatope have made charitable donations for Dr. Hayden's consulting
361 time, and both Shionogi and Roche have provided meeting travel support.

362

363 **Data Sharing Statement**

364 Relevant data can be found within the manuscript and supplemental data.

365

366 **REFERENCES**

- 367 1. World Health Organization. Influenza (seasonal) key facts. Available at:
368 [https://www.who.int/news-room/fact-sheets/detail/influenza-\(seasonal\)](https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal)). Accessed 25
369 October 2023.
- 370 2. Wright P, Neumann G, Kawaoka Y. Orthomyxoviruses. In: Fields B, Knipe D, Howley
371 P. Fields Virology. 5th ed. Philadelphia, PA: Wolters Kluwer Health/Lippincott Williams
372 & Wilkins, **2007**: 1691-1740.
- 373 3. GBD 2017 Influenza Collaborators. Mortality, morbidity, and hospitalisations due to
374 influenza lower respiratory tract infections, 2017: an analysis for the Global Burden of
375 Disease Study 2017. *Lancet Respir Med*, **2019**; 7: 69-89.
- 376 4. Mertz D, Kim TH, Johnstone J, et al. Populations at risk for severe or complicated
377 influenza illness: systematic review and meta-analysis. *BMJ*, **2013**; 347: f5061.
- 378 5. Collins JP, Campbell AP, Openo K, et al. Outcomes of immunocompromised adults with
379 laboratory-confirmed influenza in the United States, 2011–2015. *Clin Infect Dis*, **2020**;
380 70: 2121-30.
- 381 6. Becker T, Elbahesh H, Reperant LA, Rimmelzwaan GF, Osterhaus A. Influenza
382 vaccines: successes and continuing challenges. *J Infect Dis*, **2021**; 224: S405-S19.
- 383 7. Centers for Disease Control and Prevention. CDC seasonal flu vaccine effectiveness
384 studies. Available at: <https://www.cdc.gov/flu/vaccines-work/effectiveness-studies.htm>.
385 Accessed 25 October 2023.
- 386 8. Wang WC, Sayedahmed EE, Sambhara S, Mittal SK. Progress towards the Development
387 of a Universal Influenza Vaccine. *Viruses*, **2022**; 14: 1684.

- 388 9. Pizzuto M, Zatta F, Minola A, et al. VIR-2482: a potent and broadly neutralizing
389 antibody for the prophylaxis of influenza A illness. Presented at: IDWeek; 21-25 October
390 2020; Virtual. Poster #902873.
- 391 10. Plotnik D, Sager JE, Aryal M, et al. A phase 1 study in healthy volunteers to investigate
392 the safety, tolerability, and pharmacokinetics of VIR-2482: a monoclonal antibody for the
393 prevention of severe influenza A illness. *Antimicrob Agents Chemother*, **2024**;
394 e0127323.
- 395 11. Ng S, Nachbagauer R, Balmaseda A, et al. Novel correlates of protection against
396 pandemic H1N1 influenza A virus infection. *Nat Med*, **2019**; 25: 962-967.
- 397 12. De Jong NMC, Aartse A, Van Gils MJ, Eggink D. Development of broadly reactive
398 influenza vaccines by targeting the conserved regions of the hemagglutinin stem and head
399 domains. *Expert Rev Vaccines*, **2020**; 19: 563-77.
- 400 13. Paules CI, Lakdawala S, McAuliffe JM, et al. The hemagglutinin A stem antibody
401 MEDI8852 prevents and controls disease and limits transmission of pandemic influenza
402 viruses. *J Infect Dis*, **2017**; 216: 356-65.
- 403 14. Kallewaard NL, Corti D, Collins PJ, et al. Structure and function analysis of an antibody
404 recognizing all influenza A subtypes. *Cell*, **2016**; 166: 596-608.
- 405 15. Gillespie R, Cooper K, Guerra Canedo V, et al. Pre-exposure antibody prophylaxis
406 protects non-human primates from severe influenza disease. Presented at: Ninth
407 European Scientific Working Group on Influenza (ESWI) Influenza Conference; 17-20
408 September 2023; Valencia, Spain. Poster #725.

- 409 16. Food and Drug Administration (FDA). Toxicity grading scale for healthy adult and
410 adolescent volunteers enrolled in preventative vaccine clinical trials. Available at:
411 <https://www.fda.gov/media/73679/download>. Accessed 16 September 2022.
- 412 17. Osborne RH, Norquist JM, Elsworth GR, et al. Development and validation of the
413 Influenza Intensity and Impact Questionnaire (FluIIQ™). *Value Health*, **2011**; 14: 687-
414 699.
- 415 18. van Baalen CA, Jeeninga RE, Penders GH, et al. ViroSpot microneutralization assay for
416 antigenic characterization of human influenza viruses. *Vaccine*, **2017**; 35: 46-52.
- 417 19. Jayasundara K, Soobiah C, Thommes E, Tricco AC, Chit A. Natural attack rate of
418 influenza in unvaccinated children and adults: a meta-regression analysis. *BMC Infect*
419 *Dis*, **2014**; 14: 670.
- 420 20. Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of
421 influenza vaccines: a systematic review and meta-analysis. *Lancet Infect Dis*, **2012**; 12:
422 36-44.
- 423 21. Levin MJ, Ustianowski A, De Wit S, et al. Intramuscular AZD7442 (tixagevimab-
424 cilgavimab) for prevention of Covid-19. *N Engl J Med*, **2022**; 386: 2188-200.
- 425 22. Hammitt LL, Dagan R, Yuan Y, et al. Nirsevimab for prevention of RSV in healthy late-
426 preterm and term infants. *N Engl J Med*, **2022**; 386: 837-846.
- 427 23. Gostic KM, Ambrose M, Worobey M, Lloyd-Smith JO. Potent protection against H5N1
428 and H7N9 influenza via childhood hemagglutinin imprinting. *Science*, **2016**; 354: 722-
429 726.

- 430 24. McBride JM, Lim JJ, Burgess T, et al. Phase 2 randomized trial of the safety and efficacy
431 of MHAA4549A, a broadly neutralizing monoclonal antibody, in a human influenza A
432 virus challenge model. *Antimicrob Agents Chemother*, **2017**; 61: e01154-17.
- 433 25. Sloan SE, Szretter KJ, Sundaresh B, et al. Clinical and virological responses to a broad-
434 spectrum human monoclonal antibody in an influenza virus challenge study. *Antiviral
435 Res*, **2020**; 184: 104763.
- 436 26. Lim JJ, Dar S, Venter D, et al. A phase 2 randomized, double-blind, placebo-controlled
437 trial of the monoclonal antibody MHAA4549A in patients with acute uncomplicated
438 influenza A infection. *Open Forum Infect Dis*, **2022**; 9: ofab630.
- 439 27. Ali SO, Takas T, Nyborg A, et al. Evaluation of MEDI8852, an anti-influenza A
440 monoclonal antibody, in treating acute uncomplicated influenza. *Antimicrob Agents
441 Chemother*, **2018**; 62: e00694-18.
- 442 28. Hershberger E, Sloan S, Narayan K, et al. Safety and efficacy of monoclonal antibody
443 VIS410 in adults with uncomplicated influenza A infection: results from a randomized,
444 double-blind, phase-2, placebo-controlled study. *EBioMedicine*, **2019**; 40: 574-582.
- 445 29. Centers for Disease Control and Prevention. Influenza activity in the United States during
446 the 2022-23 season and composition of the 2023-24 influenza vaccine. Available at:
447 <https://www.cdc.gov/flu/spotlights/2023-2024/22-23-summary-technical-report.htm>.
448 Accessed 26 October 2023.
- 449 30. Bar-On YM, Goldberg Y, Mandel M, et al. Protection against Covid-19 by BNT162b2
450 booster across age groups. *N Engl J Med*, **2021**; 385: 2421-2430.
- 451 31. Altarawneh HN, Chemaitelly H, Ayoub HH, et al. Effects of previous infection and
452 vaccination on symptomatic Omicron infections. *N Engl J Med*, **2022**; 387: 21-34.

453 32. Tseng HF, Ackerson BK, Luo Y, et al. Effectiveness of mRNA-1273 against SARS-
454 CoV-2 Omicron and Delta variants. *Nat Med*, **2022**; 28: 1063-1071.

455

456

457 **TABLES AND FIGURES**

458 **Table 1. Baseline Characteristics (Full Analysis Set)**

	Placebo (n = 983)	VIR-2482 450 mg (n = 981)	VIR-2482 1200 mg (n = 992)	Total (N = 2956)
Age at randomization, years				
Mean (SD)	39.7 (12.3)	39.2 (12.5)	39.6 (11.7)	39.5 (12.2)
Median (range)	39.0 (18-64)	38.0 (18-64)	39.0 (18-64)	39.0 (18-64)
Sex, no. (%)				
Male	453 (46.1)	436 (44.4)	469 (47.3)	1358 (45.9)
Female	530 (53.9)	545 (55.6)	523 (52.7)	1598 (54.1)
Race, no. (%)				
American Indian or Alaskan native	7 (0.7)	7 (0.7)	7 (0.7)	21 (0.7)
Asian	26 (2.6)	26 (2.7)	29 (2.9)	81 (2.7)
Black or African American	166 (16.9)	154 (15.7)	176 (17.7)	496 (16.8)

Native Hawaiian or other Pacific Islander	4 (0.4)	5 (0.5)	4 (0.4)	13 (0.4)
White	758 (77.1)	752 (76.7)	747 (75.3)	2257 (76.4)
Multiracial	6 (0.6)	17 (1.7)	11 (1.1)	34 (1.2)
Not reported/unknown	16 (1.6)	20 (2.0)	18 (1.8)	54 (1.8)
Ethnicity, no. (%)				
Hispanic or Latino	357 (36.3)	370 (37.7)	370 (37.3)	1097 (37.1)
Not Hispanic or Latino	620 (63.1)	607 (61.9)	621 (62.6)	1848 (62.5)
Not reported/unknown	6 (0.6)	4 (0.4)	1 (0.1)	11 (0.4)
Body mass index, kg/m ²				
Mean (SD)	27.2 (4.1)	27.3 (4.1)	27.4 (4.2)	27.3 (4.1)
Median (range)	27.2 (18.0-35.0)	27.5 (18.0-36.6)	27.7 (18.0-35.1)	27.5 (18.0-36.6)
Injection site location, no. (%)				
Thigh	762 (77.5)	757 (77.2)	783 (78.9)	2302 (77.9)

Buttock	219 (22.3)	223 (22.7)	207 (20.9)	649 (22.0)
---------	------------	------------	------------	------------

459

460

461 **Table 2. Occurrence of Influenza-Like Illness With RT-PCR Confirmed Influenza A**
 462 **Through End of Influenza Season (Full Analysis Set)**

	Placebo (n = 983)	VIR-2482 450 mg (n = 981)	VIR-2482 1200 mg (n = 992)
Primary endpoint			
No. (%) participants with protocol-defined ILI ^a	25 (2.54)	24 (2.45)	21 (2.12)
Relative risk reduction vs placebo, %	-	3.78	15.85
95% CI (%) ^b	-	-67.23, 44.63	-49.27, 52.56
P-value	-	-	0.56
Secondary endpoints			
No. (%) participants with CDC-defined ILI ^a	17 (1.73)	15 (1.53)	7 (0.71)
Relative risk reduction vs placebo, %	-	11.45	57.23
95% CI (%) ^b	-	-76.25, 55.51	-2.51, 82.15
No. (%) participants with WHO-defined ILI ^a	11 (1.12)	12 (1.22)	6 (0.6)
Relative risk reduction vs placebo, %	-	-9.80	44.13
95% CI (%) ^b	-	-147.41, 51.27	-50.49, 79.26

463 CDC, Centers for Disease Control and Prevention; ILI, influenza-like illness; RT-PCR, reverse
464 transcriptase-polymerase chain reaction; WHO, World Health Organization.

465 ^aParticipants with multiple occurrences of protocol-, CDC-, or WHO-defined illness with RT-
466 PCR–confirmed influenza A were counted once.

467 ^bThe 95% CI for the primary endpoint analysis of 450 mg versus placebo and for analyses of
468 secondary endpoints are nominal, and not adjusted for multiplicity.

469 **Table 3. Occurrences of TEAEs Through the End of the Study (Safety Set)**

	Placebo (n = 983) n (%)	VIR-2482 450 mg (n = 981) n (%)	VIR-2482 1200 mg (n = 992) n (%)
Any TEAE	639 (65.0)	636 (64.8)	613 (61.8)
TEAEs by maximum toxicity grade			
Grade 1	441 (44.9)	449 (45.8)	406 (40.9)
Grade 2	181 (18.4)	174 (17.7)	190 (19.2)
Grade 3	14 (1.4)	10 (1.0)	12 (1.2)
Grade 4	3 (0.3)	3 (0.3)	5 (0.5)
Study treatment–related TEAEs	15 (1.5)	20 (2.0)	17 (1.7)
TEAEs leading to study treatment discontinuation or interruption	0	0	0
Serious TEAEs	9 (0.9)	10 (1.0)	13 (1.3)
Study treatment–related serious TEAEs	0	0	0
TEAEs leading to death ^a	0	2 (0.2)	3 (0.3)
TEAEs occurring in >5% of participants in any treatment group			
Upper respiratory tract infection	248 (25.2)	243 (24.8)	245 (24.7)
COVID-19	106 (10.8)	93 (9.5)	92 (9.3)

Oropharyngeal pain	75 (7.6)	95 (9.7)	87 (8.8)
Cough	72 (7.3)	88 (9.0)	84 (8.5)
Viral infection	70 (7.1)	56 (5.7)	48 (4.8)
Myalgia	38 (3.9)	51 (5.2)	36 (3.6)


470 TEAE, treatment-emergent adverse event.

471 A participant with multiple occurrences of the same TEAE was counted only once at the
472 maximum toxicity grade or strongest relationship to study intervention.

473 ^aReasons for death were accidental drug overdose (nontreatment intervention) and suicide (both
474 VIR-2482 450 mg), cardiac arrhythmia, cardiorespiratory arrest, and intentional multidrug
475 overdose (nontreatment intervention; all VIR-2482 1200 mg). None of the deaths were
476 considered related to study treatment.

477


478 **Figure 1. Participant Disposition**



479

480 Based on efficacy findings, the study was terminated early and follow-up into the second influenza season did not take place.

481 **Figure 2. Pharmacokinetic Profiles of VIR-2482 Following Intramuscular Administration of (A) 450-mg and (B) 1200 mg**
482 **Doses**



483

484 NPS, nasopharyngeal swab.

485 **Supplementary Methods**

486 *Participant Exclusion Criteria*

487 Participants were excluded from this study if they had an established diagnosis of a condition
488 considered high risk for developing influenza-related complications. Such conditions are listed
489 below:

- 490 • Asthma.
- 491 • Neurologic and neurodevelopmental conditions (such as cerebral palsy, epilepsy
492 [seizure disorders], stroke, intellectual disability, moderate to severe developmental
493 delay, muscular dystrophy, or spinal cord injury).
- 494 • Chronic lung disease (such as chronic obstructive pulmonary disease, emphysema,
495 and cystic fibrosis).
- 496 • Heart disease (such as congenital heart disease, congestive heart failure, and coronary
497 artery disease).
- 498 • Blood disorders (such as sickle cell disease and thalassemia).
- 499 • Endocrine disorders (such as diabetes and adrenal insufficiency).
- 500 • Chronic kidney disease.
- 501 • Chronic liver disease.
- 502 • Metabolic disorders (such as inherited metabolic disorders and mitochondrial
503 disorders).
- 504 • Weakened immune system due to disease or medication (such as individuals with
505 HIV or AIDS, or cancer, or those taking chronic steroids).
- 506 • People younger than 19 years of age who are receiving long-term aspirin therapy.

507

508 *Statistical Analysis*

509 The primary estimand was defined as the relative risk of VIR-2482 versus placebo of protocol-
510 defined ILI with central virology laboratory or point-of-care RT-PCR–confirmed influenza A in
511 the absence of RT-PCR–confirmed coinfection with influenza B, respiratory syncytial virus,
512 and/or severe acute respiratory syndrome coronavirus-2 through EOIS in the full analysis set.
513 The treatment policy strategy was used for the handling of intercurrent events of receipt of any
514 nonstudy influenza antiviral and receipt of an authorized influenza vaccine. Participants who
515 died due to influenza A were to be considered to have met the primary endpoint. Participants
516 who died for reasons other than influenza A illness were handled using the while-alive approach,
517 where data up until the time of death were included in the analysis. The secondary estimands
518 were defined similarly to the primary estimand, with all attributes being the same other than the
519 endpoints (CDC- and WHO-defined ILI with central virology laboratory or point-of-care RT-
520 PCR–confirmed influenza A in the absence of RT-PCR–confirmed coinfection with influenza B,
521 respiratory syncytial virus, and/or severe acute respiratory syndrome coronavirus-2 through
522 EOIS).

523 VIR-2482 efficacy was calculated as the relative risk reduction in the occurrence of
524 protocol-/CDC-/WHO-defined ILI with RT-PCR–confirmed influenza A in each VIR-2482
525 group compared with that in the placebo group, or $100\% \times (1 - \text{the relative risk})$, with the result
526 expressed as a percentage, with corresponding 95% CI. Participants with multiple occurrences of
527 protocol-/CDC-/WHO-defined ILI with RT-PCR–confirmed influenza A were counted once at
528 the earliest occurrence. Missing endpoint data were imputed with the observed incidence of
529 protocol-/CDC-/WHO-defined ILI with RT-PCR–confirmed influenza A in the placebo group by

530 means of multiple imputation. Exploratory analyses were conducted in predefined subgroups
531 using the same methodology as the primary efficacy endpoint.

532

533 *Hierarchical Testing*

534 For the primary estimand, the comparison of VIR-2482 450 mg versus placebo was tested only if
535 the comparison of VIR-2482 1200 mg versus placebo was statistically significant at the 0.05
536 level (2-sided). Statistical testing was to continue for each comparison for the secondary
537 estimands only if the comparison of VIR-2482 450 mg versus placebo for the primary estimand
538 was tested and statistically significant at the 0.05 level (2-sided).

539 **Supplementary Table 1. Posthoc: Participants With RT-PCR Confirmed Influenza A ILI Through EOIS, Excluding RT-PCR**
 540 **Confirmed Influenza A ILI With Onset in the First 7 Days Following Study Intervention Administration (Full Analysis Set)**

	Placebo (n = 983)	VIR-2482 450 mg (n = 981)	VIR-2482 1200 mg (n = 992)
No. (%) participants with protocol-defined ILI with RT-PCR–confirmed influenza A ^a	23 (2.3)	22 (2.2)	15 (1.5)
Relative risk reduction (95% CI) for VIR-2482 vs placebo ^b		4.14 (-70.82, 46.21)	34.01 (-25.67, 65.34)
No. (%) participants with CDC-defined ILI with RT-PCR confirmed influenza A ^a	15 (1.53)	14 (1.43)	5 (0.50)
Relative risk reduction (95% CI) for VIR-2482 vs placebo ^b		6.52 (-92.60, 54.63)	64.88 (3.87, 87.17)
No. (%) participants with WHO-defined ILI with RT-PCR–confirmed influenza A ^a	9 (0.92)	11 (1.12)	5 (0.50)

Relative risk reduction (95% CI) for VIR-2482 vs placebo ^b		-22.86 (-194.88, 48.81)	42.86 (-69.69, 80.76)
--	--	-------------------------	-----------------------

541 CDC, Centers for Disease Control and Prevention; EOIS, end of influenza season; ILI, influenza-like illness; RT-PCR, reverse
542 transcriptase-polymerase chain reaction; WHO, World Health Organization.

543 ^aParticipants with multiple occurrences of protocol-defined, CDC-defined, or WHO-defined illness with RT-PCR–confirmed
544 influenza A were counted once.

545 ^bThe 95% CIs are nominal, and not adjusted for multiplicity.

546

547

548 **Supplementary Table 2. Symptoms Among Participants With Protocol-Defined ILI With**
 549 **RT-PCR–Confirmed Influenza A Without Concomitant Coinfection Based on Flu-IIQ,**
 550 **Overall and by Maximum Severity**

Symptoms, no. (%)	Placebo (n = 983)	VIR-2482 450 mg (n = 981)	VIR-2482 1200 mg (n = 992)
Participants with any symptoms	25 (100)	23 (95.8)	21 (100)
Mild	0	1 (4.2)	2 (9.5)
Moderate	15 (60.0)	9 (37.5)	7 (33.3)
Severe	10 (40.0)	13 (54.2)	12 (57.1)
Cough	25 (100)	23 (95.8)	20 (95.2)
Mild	5 (20.0)	7 (29.2)	7 (33.3)
Moderate	16 (64.0)	10 (41.2)	10 (47.6)
Severe	4 (16.0)	6 (25.0)	3 (14.3)
Sore Throat	23 (92.0)	18 (75.0)	20 (95.2)
Mild	14 (56.0)	5 (20.8)	11 (52.4)
Moderate	7 (28.0)	9 (37.5)	7 (33.3)
Severe	2 (8.0)	4 (16.7)	2 (9.5)
Headache	21 (84.0)	19 (79.2)	21 (100)
Mild	5 (20.0)	9 (37.5)	5 (23.8)
Moderate	11 (44.0)	5 (20.8)	11 (52.4)
Severe	5 (20.0)	5 (20.8)	5 (23.8)
Nasal congestion	23 (92.0)	22 (91.7)	18 (85.7)
Mild	6 (24.0)	4 (16.7)	4 (19.1)
Moderate	13 (52.0)	14 (58.3)	9 (42.9)
Severe	4 (16.0)	4 (16.7)	5 (23.8)
Feeling feverish	21 (84.0)	18 (75.0)	18 (85.7)

Mild	5 (20.0)	7 (29.2)	6 (28.6)
Moderate	11 (44.0)	6 (25.0)	6 (28.6)
Severe	5 (20.0)	5 (20.8)	6 (28.6)
Body aches and pains	22 (88.0)	19 (79.2)	20 (95.2)
Mild	5 (20.0)	9 (37.5)	8 (38.1)
Moderate	11 (44.0)	4 (16.7)	6 (28.6)
Severe	6 (24.0)	6 (25.0)	6 (28.6)
Fatigue	25 (100)	22 (91.7)	19 (90.5)
Mild	8 (32.0)	7 (29.2)	3 (14.3)
Moderate	11 (44.0)	12 (50.0)	11 (52.4)
Severe	6 (24.0)	3 (12.5)	5 (23.8)
Neck pain	19 (76.0)	15 (62.5)	14 (66.7)
Mild	5 (20.0)	10 (41.7)	5 (23.8)
Moderate	11 (44.0)	3 (12.5)	7 (33.3)
Severe	3 (12.0)	2 (8.3)	2 (9.5)
Interrupted sleep	23 (92.0)	17 (70.8)	19 (90.5)
Mild	5 (20.0)	6 (25.0)	5 (23.8)
Moderate	10 (40.0)	5 (20.8)	8 (38.1)
Severe	8 (32.0)	6 (25.0)	6 (28.6)
Loss of appetite	23 (92.0)	18 (75.0)	18 (85.7)
Mild	11 (44.0)	9 (37.5)	9 (42.9)
Moderate	10 (40.0)	6 (25.0)	5 (23.8)
Severe	2 (8.0)	3 (12.5)	4 (19.1)

551 ILI, influenza-like illness; Flu-IIQ, Influenza Intensity and Impact Questionnaire; RT-PCR,
 552 reverse transcriptase-polymerase chain reaction.

553

554 **Supplementary Table 3. Solicited Injection-Site Reactions at 1 Hour Postdose (Safety Set)**

	Placebo (n = 983) n (%)	VIR-2482 450 mg (n = 981) n (%)	VIR-2482 1200 mg (n = 992) n (%)
Any injection-site reaction	65 (6.6)	81 (8.3)	93 (9.4)
Grade 1	63 (6.4)	79 (8.1)	90 (9.1)
Grade 2	2 (0.2)	2 (0.2)	3 (0.3)
Pain	57 (5.8)	60 (6.1)	83 (8.4)
Grade 1	55 (5.6)	60 (6.1)	83 (8.4)
Grade 2	2 (0.2)	0	0
Swelling	9 (0.9)	24 (2.5)	25 (2.5)
Grade 1	9 (0.9)	24 (2.5)	24 (2.4)
Grade 2	0	0	1 (0.1)
Erythema	2 (0.2)	2 (0.2)	4 (0.4)
Grade 1	2 (0.2)	2 (0.2)	3 (0.3)
Grade 2	0	0	1 (0.1)
Bruising	2 (0.2)	8 (0.8)	3 (0.3)
Grade 1	2 (0.2)	8 (0.8)	2 (0.2)
Grade 2	0	0	1 (0.1)
Pruritis	4 (0.4)	6 (0.6)	6 (0.6)
Grade 1	4 (0.4)	4 (0.4)	6 (0.6)
Grade 2	0	2 (0.2)	0

555 A participant with multiple reactions was counted only once for that reaction, and at the
556 maximum toxicity grade.

557

558 **Supplementary Table 4. Local Injection-Site Reactions From the Study Intervention Diary**

559 **Card (Safety Set)**

	Placebo (n = 983) n (%)	VIR-2482 450 mg (n = 981) n (%)	VIR-2482 1200 mg (n = 992) n (%)
Any injection-site reaction	272 (27.7)	292 (29.8)	293 (29.5)
Grade 1	227 (23.1)	250 (25.5)	248 (25.0)
Grade 2	38 (3.9)	35 (3.6)	39 (3.9)
Grade 3	7 (0.7)	7 (0.7)	6 (0.6)
Pain	260 (26.5)	279 (28.4)	277 (27.9)
Grade 1	222 (22.6)	240 (24.5)	237 (23.9)
Grade 2	31 (3.2)	32 (3.3)	34 (3.4)
Grade 3	7 (0.7)	7 (0.7)	6 (0.6)
Swelling	2 (0.2)	10 (1.0)	13 (1.3)
Grade 1	1 (0.1)	8 (0.8)	9 (0.9)
Grade 2	1 (0.1)	2 (0.2)	4 (0.4)
Erythema	5 (0.5)	7 (0.7)	10 (1.0)
Grade 1	4 (0.4)	6 (0.6)	10 (1.0)
Grade 2	1 (0.1)	1 (0.1)	0
Bruising	21 (2.1)	17 (1.7)	20 (2.0)
Grade 1	16 (1.6)	16 (1.6)	17 (1.7)
Grade 2	5 (0.5)	1 (0.1)	3 (0.3)

Induration	3 (0.3)	8 (0.8)	12 (1.2)
Grade 1	2 (0.2)	5 (0.5)	11 (1.1)
Grade 2	1 (0.1)	3 (0.3)	1 (0.1)

560 A participant with multiple reactions was counted only once for that reaction, and at the
561 maximum toxicity grade.

562

563

564 **Supplemental Table 5. Systemic Reactions From the Study Intervention Diary Card by**
 565 **Symptom, Overall, and by Maximum Severity (Safety Set)**

	Placebo (n = 983) n (%)	VIR-2482 450 mg (n = 981) n (%)	VIR-2482 1200 mg (n = 992) n (%)
Any systemic reaction	268 (27.3)	265 (27.0)	283 (28.5)
Mild	209 (21.3)	210 (21.4)	216 (21.8)
Moderate	53 (5.4)	42 (4.3)	52 (5.2)
Severe	6 (0.6)	13 (1.3)	15 (1.5)
Potentially life-threatening	0	0	0
Headache	175 (17.8)	160 (16.3)	168 (16.9)
Mild	138 (14.0)	125 (12.7)	124 (12.5)
Moderate	34 (3.5)	27 (2.8)	34 (3.4)
Severe	3 (0.3)	8 (0.8)	10 (1.0)
Myalgia	149 (15.2)	135 (13.8)	169 (17.0)
Mild	130 (13.2)	121 (12.3)	148 (14.9)
Moderate	17 (1.7)	13 (1.3)	17 (1.7)
Severe	2 (0.2)	1 (0.1)	4 (0.4)
Malaise	123 (12.5)	117 (11.9)	130 (13.1)
Mild	101 (10.3)	96 (9.8)	98 (9.9)
Moderate	20 (2.0)	18 (1.8)	28 (2.8)

Severe	2 (0.2)	3 (0.3)	4 (0.4)
Shivering	43 (4.4)	44 (4.5)	60 (6.1)
Mild	38 (3.9)	33 (3.4)	43 (4.3)
Moderate	4 (0.4)	10 (1.0)	13 (1.3)
Severe	1 (0.1)	1 (0.1)	4 (0.4)
Fever ^a	13 (1.3)	11 (1.1)	11 (1.1)
Mild	7 (0.7)	6 (0.6)	8 (0.8)
Moderate	5 (0.5)	3 (0.3)	2 (0.2)
Severe	1 (0.1)	2 (0.2)	1 (0.1)
Potentially life-threatening	0	0	0

566 A participant with multiple reactions was counted only once for that reaction, and at the
 567 maximum grade.

568 ^aFever was graded using the Toxicity Grading Scale for Healthy Adult and Adolescent
 569 Volunteers Enrolled in Preventative Vaccine Clinical Trials.

570 **Supplementary Table 6. Influenza A Subtypes for Participants With Protocol-Defined ILI**
 571 **With RT-PCR Confirmed Influenza A Without Concomitant Coinfection (Virology**
 572 **Analysis Set)**

	Placebo (n = 593)	VIR-2482 450 mg (n = 579)	VIR-2482 1200 mg (n = 574)
No. (%) participants ^a	25 (4.2)	24 (4.2)	21 (3.7)
No. of protocol-defined ILI with RT-PCR-confirmed influenza A (without coinfection), N1	25	25	21
H1 pdm09, no. (%)	9 (36.0)	4 (16.0)	5 (23.8)
H3, no. (%)	14 (56.0)	18 (72.0)	12 (57.1)
Unknown, no. (%)	2 (8.0)	3 (12.0)	4 (19.1)

573 ILI, influenza-like illness; RT-PCR, reverse transcriptase-polymerase chain reaction.

574 ^aIf a participant had multiple protocol-defined ILI with RT-PCR–confirmed influenza A without
 575 coinfection, all (N1) were included in the summary. Percentages for influenza A subtypes are
 576 based on N1.

577

578

579 **Supplementary Table 7: Sequence and Phenotypic Data Availability for Participants With**
580 **RT-PCR Confirmed Influenza A Virus (Safety Set)**

Study Population	Placebo	VIR-2482 450 mg	VIR-2482 1200 mg	Total
	n/N ^a (%)			
Participants with HA sequence data available	14/29 (48.3)	18/30 (60.0)	12/24 (50.0)	44/83 (53.0)
Participants with phenotypic data available	15/29 (51.7)	17/30 (56.7)	10/24 (41.7)	42/83 (50.6)

581 RT-PCR, reverse transcriptase-polymerase chain reaction.

582 ^an is number of participants with sequence or phenotypic data available; N is number of

583 participants with RT-PCR confirmed influenza A in the safety set.

584 **Supplementary Table 8: Serum PK Parameters (PK Analysis Set)**

PK parameter (unit)	VIR-2482 450 mg			VIR-2482 1200 mg		
	Thigh	Buttock	Total	Thigh	Buttock	Total
C_{max} ($\mu\text{g/mL}$)						
n	636	189	826	657	172	829
Geometric mean	55.6	30.9	48.6	128	64.8	111
Geometric CV%	39.2	65.5	53.6	33.7	67.8	52.1
C_{180} ($\mu\text{g/mL}$)						
n	636	189	826	657	172	829
Geometric mean	6.1	4.2	5.6	14	8.3	12.6
Geometric CV%	124.8	70.7	114.8	130.6	93.3	127.4
AUC_{0-180} ($\text{d} \cdot \mu\text{g/mL}$)						
n	636	189	826	657	172	829
Geometric mean	3960	2430	3540	9140	5030	8070
Geometric CV%	39.9	57.1	49.6	36.3	58.9	49.4
AUC_{∞} ($\text{d} \cdot \mu\text{g/mL}$)						

n	240	82	322	253	71	324
Geometric mean	3970	2760	3620	9070	5830	8230
Geometric CV%	45.3	58.1	51.8	46.9	64.3	55.0
CL/F (mL/d)						
n	240	82	322	253	71	324
Geometric mean	113	163	124	132	206	146
Geometric CV%	45.3	58.1	51.8	46.9	64.3	55.0
V_z/F (L)						
n	240	82	322	253	71	324
Geometric mean	7.9	12.8	9.0	9.2	15.7	10.3
Geometric CV%	34.7	55.6	46.6	30.1	61.0	45.0
T_{max} (d)						
n	636	189	826	657	172	829
Median	7.0	7.2	7.0	6.9	7.8	7.0
Min, max	2.8, 40.9	4.1, 35.8	2.8, 40.9	1.9, 57.9	4.9, 71.1	1.9, 71.1
$T_{1/2}$ (d)						

n	249	85	334	272	71	343
Median	55.1	56.7	55.4	54.5	55.7	54.7
Min, max	15.5, 76.7	26.1, 76.8	15.5, 76.8	14, 79	15.3, 77	14, 79

585 AUC_{∞} , area under the concentration-time curve extrapolated from time zero to time infinity; AUC_{0-180} , partial area under the
586 concentration-time curve from time zero to day 180; CL/F, total body clearance following extravascular administration; C_{max} ,
587 maximum observed serum concentration; C_{180} , predicted serum concentration at day 180; CV, coefficient of variation; PK,
588 pharmacokinetics; T_{max} , time at which maximum serum concentration was observed; $T_{1/2}$, terminal elimination half-life; V_z/F , apparent
589 volume of distribution during the terminal elimination phase, following extravascular administration point.

590

591 **Supplementary Table 9: PK and Virology Data From Protocol-Defined ILI Cases**

Location	Date of dose	Date of protocol-defined ILI	Days elapsed from dose to protocol-defined ILI	VIR-2482 serum concentration (µg/mL)	VIR-2482 NPS concentration (µg/mL)	Influenza A subtype
Buttock 450 mg	2022-11-01	2022-11-24	24	18.0	0.6	H3
	2022-11-07	2022-11-26	20	37.5	NC	H3
	2022-10-28	2022-11-03	7	18.9	NC	H1pdm09
Buttock 1200 mg	2022-11-04	2022-12-04	31	15.9	2.1	H3
	2022-11-17	2022-11-30	14	–	NC	Unknown
Thigh 450 mg	2022-11-21	2022-12-19	29	32.4	NC	H3
	2022-11-11	2022-12-01	21	46.1	NC	Unknown
	2022-11-21	2022-12-05	15	45.0	NC	H3
	2022-11-02	2022-12-01	30	15.9	NC	H1pdm09
	2022-11-16	2022-11-28	13	70.4	–	Unknown
	2022-11-10	2022-11-21	12	65.1	NC	H3

	2022-11-08	2022-12-28	51	35.8	NC	H3
	2022-11-11	2022-11-23	13	37.8	NC	H3
	2022-11-28	2023-01-12	46	BQL	NC	H1pdm09
	2022-11-15	2022-12-13	29	47.0	NC	H3
	2022-10-28	2022-12-01	35	53.4	NC	H3
	2022-11-28	2023-02-13	78	34.6	NC	H3
	2022-11-28	2023-02-13	78	25.1	NC	H3
	2022-11-18	2022-11-21	4	74.6	2.8	H3
	2022-11-28	2022-12-12	15	80.8	NC	H3
	2022-10-26	2022-11-23	29	26.3	NC	H3
	2022-11-09	2022-12-15	37	28.0	2.5	H3
	2022-11-10	2022-11-24	15	46.7	1.0	H3
	2022-11-08	2022-12-21	44	27.8	–	Unknown
	2022-11-16	2022-12-07	22	58.1	–	H1pdm09
	2022-11-16	2022-11-24	9	66.8	NC	H3
Thigh 1200 mg	2022-11-16	2022-11-19	4	205.6	NC	H3

	2022-11-10	2022-11-13	4	102.5	0.7	H3
	2022-11-17	2022-12-05	19	98.2	NC	H3
	2022-11-28	2022-12-27	30	69.7	2.4	H3
	2022-12-01	2022-12-08	8	169.2	0.9	H3
	2022-12-01	2022-12-05	5	119.0	NC	H3
	2022-11-28	2022-12-02	5	173.5	4.2	H1pdm09
	2022-11-22	2022-12-10	19	170.4	NC	H3
	2022-11-07	2022-11-28	22	119.9	NC	H3
	2022-10-28	2022-11-10	14	122.0	–	Unknown
	2022-10-19	2023-03-15	148	33.4	NC	H1pdm09
	2022-12-05	2022-12-15	11	101.5	NC	H1pdm09
	2022-11-07	2022-12-04	28	103.9	NC	H1pdm09
	2022-12-05	2022-12-05	1	43.3	NC	H3
	2022-10-26	2022-12-12	48	57.8	–	Unknown
	2022-11-22	2022-12-05	14	94.1	2.6	H3
	2022-11-15	2022-12-01	17	83.6	3.0	H1pdm09


	2022-12-01	2022-12-28	28	116.9	–	Unknown
	2022-12-02	2022-12-12	11	126.3	0.8	H3

592 BQL, below the quantification limit; PK, pharmacokinetics; ILI, influenza-like illness; NC, not calculable; NPS, nasopharyngeal swab.

593

594

595 **Supplementary Figure 1. Subgroup Analyses for the Occurrence of Protocol-Defined**
 596 **Influenza-Like Illness With RT-PCR Confirmed Influenza A in Participants Receiving**
 597 **VIR-2482 1200 mg**




598

599 BMI, body mass index; NC, not calculable; RT-PCR, reverse transcriptase-polymerase chain reaction.

600

601 **Supplementary Figure 2. VIR-2482 NPS:Serum Ratios by Dose and Timepoint (PK**
602 **Analysis Set)**



603
604 EOIS, end of influenza season; NPS, nasopharyngeal swab; PK, pharmacokinetics.
605 The ratio of VIR-2482 in NPS samples versus serum is calculated as $100 \times (\text{VIR-2482 NPS}$
606 $\text{concentration} / \text{VIR-2482 serum concentration})$.